Losartan: A Comprehensive Pharmacology Review for Clinicians and Students

Losartan is more than a blood‑pressure‑lowering agent; it is a linchpin in the management of hypertension, diabetic nephropathy, and heart failure. In 2023, the American Heart Association reported that one in five adults with chronic kidney disease remains on an angiotensin receptor blocker, underscoring the drug’s clinical ubiquity. Imagine a 58‑year‑old man with stage 3 chronic kidney disease whose serum creatinine rises from 1.2 to 1.8 mg/dL after switching from a calcium channel blocker to losartan—an everyday scenario that highlights the drug’s dual role as a hemodynamic modulator and a renoprotective agent.

Introduction and Background

Losartan was first approved by the FDA in 1995 as an angiotensin II type 1 (AT1) receptor antagonist. Its development stemmed from the seminal work of Dr. John C. McDonald and colleagues, who demonstrated that selective blockade of the AT1 receptor could attenuate vasoconstriction and aldosterone secretion without the bradykinin‑mediated cough associated with ACE inhibitors. Losartan’s introduction marked a paradigm shift in antihypertensive therapy, offering a more favorable side‑effect profile for patients prone to cough or angioedema.

Hypertension remains the leading modifiable risk factor for cardiovascular morbidity, affecting nearly 45% of adults in the United States. The renin‑angiotensin‑aldosterone system (RAAS) is a central driver of blood‑pressure regulation and extracellular fluid homeostasis. By targeting the AT1 receptor, losartan interrupts the cascade that leads to systemic vasoconstriction, sodium retention, and sympathetic activation. Beyond its antihypertensive action, losartan’s ability to reduce intraglomerular pressure confers renoprotection, a property that has been validated in landmark trials such as the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) study and the RENAAL trial.

Mechanism of Action

AT1 Receptor Antagonism

Losartan binds reversibly to the AT1 receptor located on vascular smooth muscle cells, cardiac myocytes, and renal tubular epithelial cells. By occupying the angiotensin II binding site, it prevents receptor activation, thereby inhibiting the downstream Gq‑protein signaling pathway that normally culminates in phospholipase C activation, intracellular calcium mobilization, and smooth‑muscle contraction.

Modulation of Aldosterone Secretion

In the adrenal zona glomerulosa, angiotensin II stimulates aldosterone synthesis via the AT1 receptor. Losartan’s blockade reduces aldosterone release, diminishing sodium reabsorption in the distal nephron and promoting natriuresis. This effect also mitigates volume expansion and contributes to the drug’s antihypertensive potency.

Influence on Endothelial Function and Inflammation

By dampening AT1‑mediated reactive oxygen species production, losartan improves endothelial nitric oxide availability. Additionally, it down‑regulates pro‑inflammatory cytokines such as interleukin‑6 and tumor necrosis factor‑α, thereby exerting anti‑fibrotic and anti‑remodeling effects that are particularly valuable in chronic kidney disease and heart failure.

Clinical Pharmacology

Pharmacokinetics

Losartan is available as a 25, 50, 100, and 150 mg oral tablet. The drug is absorbed rapidly, with peak plasma concentrations reached within 2–3 hours post‑dose. The absolute bioavailability is approximately 30% due to first‑pass metabolism. Losartan is a prodrug; its active metabolite, EXP3174, is formed via oxidative O‑demethylation by the cytochrome P450 2C9 (CYP2C9) enzyme. The metabolite has a half‑life of 6–9 hours, compared to 2–3 hours for the parent compound, resulting in a cumulative exposure that sustains therapeutic effects over 24 hours.

Distribution is extensive, with a volume of distribution of 1.5–2.0 L/kg. Plasma protein binding is moderate (30–40%), primarily to albumin. Losartan and EXP3174 are excreted via the kidneys (70% of the dose) and bile (30%). Renal clearance is reduced by 30–40% in patients with moderate renal impairment (creatinine clearance 30–59 mL/min), necessitating dose adjustment. Hepatic impairment has a minimal impact on pharmacokinetics, allowing the use of standard dosing in mild to moderate liver disease.

Pharmacodynamics

The dose‑response relationship for losartan is sigmoidal, with a maximal blood‑pressure‑lowering effect achieved at 100 mg daily. The therapeutic window is broad; however, the risk of hyperkalemia and renal dysfunction increases markedly at doses above 150 mg in susceptible populations. Losartan’s antihypertensive effect is additive when combined with diuretics or calcium channel blockers, a synergy that is reflected in the 5–10 mmHg greater systolic reduction observed in combination studies.

Therapeutic Applications

• Hypertension: 25–150 mg once daily, titrated to achieve target blood pressure.
• Diabetic Nephropathy (Type 2): 50 mg daily; reduces albuminuria by ~30% and slows progression to end‑stage renal disease.
• Heart Failure with Reduced Ejection Fraction: 50 mg daily; improves mortality and hospitalizations when added to standard therapy.
• Post‑Myocardial Infarction: 50–100 mg daily; reduces remodeling and improves survival.
• Primary Aldosteronism (non‑surgical): 50–100 mg daily; lowers blood pressure and reduces potassium wasting.
• Off‑Label – Polycystic Kidney Disease: Evidence suggests slowed cyst growth; data remain preliminary.
• Special Populations: Pediatrics: 0.1–0.3 mg/kg/day; Geriatrics: standard dosing with close monitoring; Renal impairment: dose reduction to 25 mg daily if eGFR <30 mL/min/1.73 m²; Pregnancy: contraindicated in all trimesters.

Adverse Effects and Safety

Common side effects include dizziness (12–15%), cough (5–7%), and hyperkalemia (3–5%). The incidence of cough is markedly lower than with ACE inhibitors, making losartan a preferred agent for patients with a history of cough or angioedema. Serious adverse events such as angioedema, hypotension, and acute renal failure are rare (<1%).

Black box warnings include: Pregnancy Category X (risk of fetal renal dysgenesis), Contrast‑induced nephropathy (when used with iodinated contrast), and Hyperkalemia (especially in patients on potassium‑sparing diuretics or potassium supplements).

Monitoring parameters include baseline serum creatinine and potassium, followed by reassessment at 1–2 weeks and then monthly for the first 3 months. Blood pressure should be checked at each visit, and patients should be educated to report symptoms of dizziness, syncope, or swelling.

Contraindications are: Hypersensitivity to losartan or any ARB component, Pregnancy, and Concurrent use with aliskiren in patients with diabetes or renal impairment.

Clinical Pearls for Practice

• PEARL: P‑Dose (Start low), E‑Adjust (titrate), A‑Avoid NSAIDs, R‑Renal function, L‑Look for hyperkalemia.
• Remember the “Cough” Mnemonic: Losartan = Low cough risk vs ACE inhibitors = High cough risk.
• Combination Therapy: Add losartan to a calcium channel blocker for better ambulatory BP control while minimizing diuretic‑induced electrolyte shifts.
• Renal Protection: In diabetic patients with albuminuria, losartan reduces progression to ESRD by ~30% within 3 years.
• Hyperkalemia Check: Screen all patients on ARBs who are on potassium supplements or potassium‑sparing diuretics every 2–4 weeks.
• Contrast Imaging: Discontinue losartan 24 hours before iodinated contrast studies in patients with eGFR <60 mL/min/1.73 m².
• Pregnancy Alert: A single dose in the first trimester can cause fetal renal dysgenesis; counsel patients on contraception.

Comparison Table

Exam‑Focused Review

Question Stem 1: A 62‑year‑old man with stage 2 CKD and uncontrolled hypertension is switched from lisinopril to losartan. Which laboratory value is most likely to rise after the switch?

Answer: Serum potassium – due to decreased aldosterone‑mediated potassium excretion.

Question Stem 2: A patient on losartan develops an acute rise in serum creatinine after starting ibuprofen. What is the most appropriate next step?

Answer: Discontinue NSAID; monitor renal function; consider alternative analgesic.

Key Differentiators:

• ARBs block AT1 receptors; ACE inhibitors block angiotensin‑converting enzyme.
• ARBs rarely cause cough; ACE inhibitors frequently do.
• Both increase potassium, but ARBs have a slightly higher risk of hyperkalemia.
• ARBs are preferred in patients with cough or angioedema.

Must‑know facts for NAPLEX/USMLE:

1. Losartan’s active metabolite EXP3174 accounts for >50% of its antihypertensive effect.
2. Contraindicated in pregnancy due to fetal renal dysgenesis.
3. Use with caution in patients with renal impairment; dose reduction to 25 mg daily if eGFR <30.
4. Combination with diuretics or calcium channel blockers yields additive BP lowering.
5. Monitor potassium and creatinine when initiating or titrating dose.
6. Discontinue 24 hours before iodinated contrast in patients with eGFR <60.
7. Hyperkalemia risk increases with potassium‑sparing diuretics or potassium supplements.
8. Losartan has a favorable side‑effect profile compared to ACE inhibitors in patients prone to cough.

Key Takeaways

1. Losartan is a first‑line ARB for hypertension and diabetic nephropathy.
2. Its active metabolite EXP3174 provides sustained antihypertensive activity.
3. Start at 25 mg daily; titrate to 100–150 mg based on BP response.
4. Monitor serum creatinine and potassium, especially in renal impairment.
5. Contraindicated in pregnancy; risk of fetal renal dysgenesis.
6. Combination with diuretics or calcium channel blockers enhances BP control.
7. Hyperkalemia is the most common serious adverse effect; avoid concomitant potassium‑sparing agents.
8. Losartan is preferred over ACE inhibitors in patients with cough or angioedema.
9. Discontinue 24 hours before iodinated contrast in patients with reduced eGFR.
10. Use with caution in elderly; monitor for orthostatic hypotension.

Always counsel patients on the importance of adherence, monitoring for hyperkalemia, and avoiding over‑the‑counter potassium supplements while on losartan.